All News

obese.waist_.jpg

Weekly Semaglutide for Weight Loss in Adults

Jack Cush, MD

NEJM has reported the results of a trial showing semaglutide once weekly plus lifestyle intervention was associated with sustained, weight loss in overweight or obese adults; such that nearly one-third lost over 20% of their body weight.

Read Article
COVID vaccine vials

ACR Promotes New COVID-19 Vaccine Clinical Guidance for Rheumatic Patients

Jack Cush, MD

The American College of Rheumatology has published a draft guidance on the use of COVID-19 vaccination in rheumatic disease and musculoskeletal disease patients, based on the efforts of the North American Task force. The document provides guidance to rheumatology providers on the use of the COVID-19 vaccine and the associated management of RMD patients around the time of vaccination. Here is a summary of the recommendations.

Read Article
cardiac2.jpg (keep)

Comorbidity and Drugs Drive COVID-19 Severity and Survival in Rheumatic Disease

Jack Cush, MD

While comorbidities are associated with severe COVID-19 infection, it appears they also influence severity and survival in rheumatic disease (RMD), according to a a French cohort study,

Read Article
RheumNow Podcast square

RheumNow Podcast – Tofacitinib Safety Concerns (2.5.2021)

Jack Cush, MD

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Read Article
infusion.biologic.jpg

Low Persistence of Biologics in Psoriatic Arthritis

Jack Cush, MD

A longitudinal observational cohort study of psoriatic arthritis (PsA) patients treated with biologic therapy finds relatively low persistence of selected biologic therapy in PsA patients

Read Article
patient.safety.jpg

JAK Inhibitor Misses Endpoint in Safety Study. Now What?

MedPage Today

Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.

Read Article
No increased risk of cancer with TNFi use in PsA patients @RWCSmtg @JointMD https://t.co/7VSI1Fd1hw
Dr. John Cush RheumNow ( View Tweet)
Partial control of #PsA on MTX- Control study shows that adding adalimumab is superior to just escalating MTX @RWCSmtg @JointMD https://t.co/nDWzf4HYwp
Dr. John Cush RheumNow ( View Tweet)
Drs. Kavanaugh, Ruderman, Ogdie at @RWCSmtg on the multiple domains of psoriatic arthritis #PsA @JointMD https://t.co/3uS6JxdfIR
Dr. John Cush RheumNow ( View Tweet)

We are excited to announce that Dr. Eric Ruderman ( @JointMD) will be speaking on advancing treatments in psoriatic arthritis at RheumNow Live, March 20-21. There's still time to sign up. https://t.co/vJlU0Z3Q3x https://t.co/T0V8JIygyA

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic Podcast from Last week. iTunes https://t.co/FHJv01AAbC or SoundCloud https://t.co/dfSTkSbY2d QD Clinics (123-127; Feb 5) QD127 - Chronic Monarthritis QD126 - Fever by the Numbers QD125 - "What Were You Thinking" QD124 - No Win Consults QD123 - When RA Meets UC https://t.co/ReOFOVooje

Links:

Dr. John Cush RheumNow ( View Tweet)
Consults in Cars--have telehealth consults gone too far? https://t.co/INbKZ3xxty https://t.co/X2RwktCd2U

Links:

Dr. John Cush RheumNow ( View Tweet)
Low Persistence of Biologics in Psoriatic Arthritis A longitudinal observational cohort study of psoriatic arthritis (PsA) patients treated with biologic therapy finds relatively low persistence of selected biologic therapy in PsA patients. https://t.co/CzQnpAnttW https://t.co/uYU778rwod

Links:

Dr. John Cush RheumNow ( View Tweet)
Abbvie has released data from KEEPsAKE-1 and KEEPsAKE-2 studies (1407 pts) showing Risankizumab (IL--23 inhibitor) is effective in Psoriatic arthritis; RIS Rx pts achieved ACR20 of 57% and 51% at week 24 (vs PBO 34% and 27%; p<0.001) https://t.co/wPQMqLnhOO

Links:

Dr. John Cush RheumNow ( View Tweet)

Sign up for RheumNow Live, March 20 and 21st. CME credits available. https://t.co/uwxOVh142F https://t.co/GqkCLBGl62

Links:

Dr. John Cush RheumNow ( View Tweet)
Several studies have shown that Xray progression has lessened in recent yrs - presumeably from more aggressive Rx by Rheums! Still - Predictors of Xray long term damage = high ESR/CRP, baseline xray damage, -CCP/RF positivity https://t.co/2iaMiaquEV https://t.co/cgEP4QBvL4

Links:

Dr. John Cush RheumNow ( View Tweet)

SELECT-PsA2, UPA vs PLBO in refractory PsA, @ARD_BMJ Better ACR20 (57% vs 24% PLBO, NNT~3) and ACR50 (32% vs 5% PLBO, NNT~4). Decent PASI 90 (30% vs 6%, NNT~4) Similar adverse events to RA pop. Nice to have another option, esp in refractory dx! https://t.co/Zz2WYqswT2
Mike Putman EBRheum ( View Tweet)
Rheums: Got a Rheumatology question or case for RheumNow? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/wzNmOzH4VE https://t.co/6w8CAAUkO6

Links:

Dr. John Cush RheumNow ( View Tweet)
The EMA has Approved AbbVie’s Upadacitinib (Rinvoq) in the EU for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis. https://t.co/H5E8dazQx4

Links:

Dr. John Cush RheumNow ( View Tweet)

Systematic review (39 studies 152K patients) of comorbidities in Psoriatic arthritis; most common were HTN 34%, metabolic syndr 29%, obesity 27%, hyperlipidaemia 24% &CV Dz 19%. Comorbid pts: more severe dz, worse QOL & more drug discontinuation https://t.co/VxyYlPltDc

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×